An official website of the United States government
Home
Name
Gazyva
Alternate Names
GA101
Obinutuzumab
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
monoclonal antibody
NSC Number
None
Primary Site
Bone marrow
Histology
Chronic lymphocytic leukemia (CLL)
Remarks
November 1, 2013: Gazyva received FDA approval for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia. Gazyva was the first drug to receive breakthrough therapy designation from the FDA.
No NSC number available for this drug
February 26, 2016: The FDA approved Gazyva plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not rsepond to a Rituxan-containing regimen, or whose follicular lymphoma returned after such treatment.
No NSC number available for this drug
February 26, 2016: The FDA approved Gazyva plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not rsepond to a Rituxan-containing regimen, or whose follicular lymphoma returned after such treatment.
Coding
This drug should be coded
